Clinical trials offer access to treatments that aren't yet available through standard care. For some conditions — particularly rare cancers and treatment-resistant diseases — a trial may represent the best available option. Yet most patients never explore this pathway, often because nobody mentions it.
How to find relevant trials
The NIHR Be Part of Research portal lists all active UK trials searchable by condition. ClinicalTrials.gov covers international trials including those with UK sites. Cancer Research UK maintains a dedicated trial search for oncology patients.
But searching databases yourself is only the starting point. The language of eligibility criteria is technical, and a condition that sounds like yours may have exclusion criteria that disqualify you. Conversely, trials you wouldn't have found may be relevant if your condition is reclassified or if you meet molecular or genetic criteria.
Why timing is critical
This is the most common mistake: starting standard treatment before checking trial eligibility. Many trials require patients to be "treatment-naive" — meaning they haven't yet received certain therapies. Once you've started a standard chemotherapy regimen, you may be permanently disqualified from trials that could have offered a better option.
The window between diagnosis and treatment initiation is when trial eligibility should be assessed. Not after months of standard treatment have narrowed your options.
What participation actually involves
Trial participation doesn't mean you're a guinea pig. Phase III trials compare a new treatment against the current best standard — so you'll receive at least the standard of care. Monitoring is typically more intensive than standard treatment, meaning more frequent check-ups and scans. And you can withdraw at any time.
The practical concerns — travel to trial sites, time off work, additional appointments — are real and should be weighed against the potential benefit. But they should be weighed with full information, not dismissed out of unfamiliarity.